India Weekly Issue 04

US PRESIDENT Donald Trump

last week announced a deal

with AstraZeneca that he said

would reduce drug prices in the

United States in exchange for

delaying new tariffs on the Brit­

ish pharmaceutical company.

The agreement follows a

similar accord with Pfizer an­

nounced last month. Under the

deal, AstraZeneca will offer

“Most Favored Nation” pricing

to Medicaid, meaning it will

match the lowest prices

charged for its medicines in

other high-income countries.

Officials said the company

also agreed to join a new web­

site called TrumpRx, which

will allow Americans to buy

drugs directly at reduced pric­

es. Mehmet Oz, head of the

Centers for Medicare and Med­

icaid Services, said AstraZene­

ca would provide heavily dis­

counted drugs for lung disease

as part of the arrangement.

In return, the Trump admin­

istration will delay new tariffs

on AstraZeneca for three years.

The company had earlier

pledged to invest $50 billion in

the United States amid con­

cerns over potential trade mea­

sures. “Most of our products

are locally manufactured, but

we need to transfer the remain­

ing part to this country,” Astra­

Zeneca CEO Pascal Soriot said

at a White House event with

Trump and other officials.

The announcement comes

after Trump’s September

30 agreement with Pfizer,

which also included three-year

tariff relief.

Drug prices remain a major

political issue in the United

States, though the impact of

recent measures is still uncer­

tain. Shares of Pfizer and

other pharmaceutical firms

rose after last month’s an­

nouncement, suggesting inves­

tors expect limited profit ef­

fects. “From a company per­

spective, you have more visibil­

ity going forward,” said CFRA

Research analyst Sel Hardy. He

added that it was too early to

gauge the overall impact of the

administration’s policies, which

include upcoming negotiations

on 15 major drugs in November

under a 2022 law. (With inputs

from agencies)

Trump delays AstraZeneca tariffs in exchange for cheaper drugs

US PRESIDENT Donald Trump’s decision to sharply

increase H-1B visa fees is prompting American com­

panies to consider moving more high-value work to

India. Economists and industry experts say the

move could speed up the growth of global capability

centers (GCCs) that manage operations such as fi­

nance, technology, and research and development.

India is home to about 1,700 GCCs, more than half the

global total. These centers, which started as back-office

support units, now play a major role in product design,

innovation, and other specialized areas, including auto­

motive design and pharmaceutical research.

Rising visa costs and tightening rules are forcing US

firms to review their hiring and labor strategies. Many

are now turning to India-based GCCs, which combine

global talent with local leadership and can handle criti­

cal business functions.

“GCCs are uniquely positioned for this moment. They

serve as a ready in-house engine,” said Rohan Lobo,

partner and GCC industry leader at Deloitte India. He

said several US firms are already reassessing workforce

plans. “Plans are already underway,” he added, pointing

to increased activity in financial services and technology

sectors, especially among companies involved in US

federal contracts.

Lobo said he expected GCCs in India to “take on more

strategic, innovation-led mandates” over time.

Earlier this month, Trump raised the cost of new H-1B

visa applications to $100,000, from the earlier range of

$2,000 to $5,000. The move adds pressure on American

companies that depend on foreign skilled workers to fill

key roles.

Separately, US senators this week reintroduced a bill

to tighten H-1B and L-1 visa programs, saying it aims to

close loopholes and prevent misuse by large employers.

If these curbs remain, industry experts say more US

firms will shift advanced work related to artificial intel­

ligence, product development, cybersecurity, and ana­

lytics to their India-based GCCs. Many companies prefer

keeping such work in-house through GCCs rather than

outsourcing it to third-party vendors.

“There is a sense of urgency,” said Lalit Ahuja, found­

er and CEO of ANSR, which has helped companies such

as FedEx, Bristol-Myers Squibb, Target, and Lowe’s set

up their GCCs in India.

Firms revisit India plans

Ramkumar Ramamoorthy, former managing director of

Cognizant India, said the new visa rules could trigger

“extreme offshoring” in some cases. He noted that the

COVID-19 pandemic had already shown that critical

technology work could be done from anywhere.

US government data shows that Amazon, Microsoft,

Apple, Google parent Alphabet, JPMorgan Chase, and

Walmart are among the largest sponsors of H-1B visas. All

of them have major operations in India but declined to

comment because of the political sensitivity of the issue.

“Either more roles will move to India, or corporations

will near-shore them to Mexico or Colombia. Canada

could also take advantage,” said the India head of a retail

GCC. Even before the new fee hike and plans for a selec­

tion process favoring higher-paid roles, India was pro­

jected to host GCCs for more than 2,200 companies by

2030, with a total market size nearing $100 billion. “This

whole ‘gold rush’ will only get accelerated,” Ahuja said.

Cautious outlook amid policy risks

Some companies remain cautious and are adopting a

“wait and watch” approach.

They are concerned about the proposed HIRE Act,

which would impose a 25 per cent tax on US companies

outsourcing work overseas. The measure could disrupt

India’s services exports and alter outsourcing strategies.

“For now, we are observing and studying, and being

ready for outcomes,” said the India head of a US drug­

maker’s GCC.

Trade tensions between India and the United States

have extended from goods to services. Visa restrictions

and the proposed outsourcing tax could affect India’s

cost advantage and slow the flow of cross-border ser­

vices. India’s $283 billion information technology indus­

try, which contributes nearly 8 per cent of the country’s

GDP, may feel some impact. However, growing demand

for GCC services could offset part of the pressure.

“Lost revenues from H-1B visa reliant businesses

could be somewhat supplanted by higher services ex­

ports through GCCs, as US-based firms look to bypass

immigration restrictions to outsource talent,” Nomura

analysts said in a research note last week. (With inputs

from Reuters)

RISING COSTS RESHAPE GLOBAL HIRING AND STRENGTHEN INNOVATION NETWORKS

Business

www.indiaweekly.biz • October 2025

15

Visa curbs spur US firms

to build India centres

AN EMPLOYEE of a US-

based company said he

and several others in In­

dia were abruptly fired

during a four-minute

online meeting, sparking

outrage on social media.

The worker shared his

experience on Reddit,

saying he received a

sudden calendar invite

for a mandatory meet­

ing with the company’s

COO. “He joined at 11:01,

disabled everyone’s

cameras and mics, and

casually let us know they

had ‘made the difficult

decision of letting most

of their Indian workforce

go,’” the employee

wrote. The COO said the

move was due to inter­

nal restructuring and not

performance issues.

According to the post,

affected employees

were told they would re­

ceive follow-up emails

with details. The worker

said the announcement

ended without any op­

portunity for questions,

leaving staff “shocked

and unprepared.” He

added that October’s

salary would be paid at

the end of the month

and unused leave would

be encashed.

The post drew wide

reactions online, with us­

ers criticizing the “brutal”

handling of the layoffs

and offering words of

support and job refer­

rals. Several shared sim­

ilar experiences and

called for stronger labor

protections for re­

mote employees.

The layoffs come amid

growing debate over US

visa policy changes and

rising concerns about

global job security.

Indian staff

fired over

video call

TALENT SHIFT: Employees

of Indian IT services

exporter LTIMindtree work

inside its office in Bengaluru

© Reuters

© iStock

PHARMA PACT: US president Donald Trump speaks

at the White House during an event announcing a

deal to lower drug prices, attended by senior

officials and AstraZeneca CEO Pascal Soriot

© Reuters